Item 8.01. Other Events.

As previously reported in a Current Report on Form 8-K (the "Original 8-K") filed on September 23, 2021 (the "Disclosure Date"), on the Disclosure Date, Solid Biosciences Inc. (the "Company") reported 1.5-year functional data and patient-reported outcome measures for patients four through six in the Company's ongoing IGNITE DMD Phase I/II clinical trial of SGT-001, all of whom received 2E14 vg/kg of SGT-001 manufactured using the Company's first-generation manufacturing process. In the Original 8-K, the Company's press release issued on the Disclosure Date and the presentation at the World Muscle Society 2021 Virtual Congress on the Disclosure Date, the percent predicted forced vital capacity ("FVC") disclosed for patient five contained a numerical error which is corrected in this Amendment to Form 8-K.

FVC Functional Data

The FVC for patients four through six continued to show stability or improvement 1.5 years following SGT-001 administration, while natural history analyses suggest that similarly aged patients to those enrolled in IGNITE DMD would normally be expected to exhibit a decline of 7.5% over the same time period. The mean improvement in percent predicted FVC from baseline to 1.5 years for patients four through six was 8.5% (Range: +0.6% to +22.5%), and the mean difference compared with natural history data was +16.0% over the same time period.

The following table summarizes the 1 year and 1.5 year FVC functional data of IGNITE DMD for patients treated with the high dose 2E14 vg/kg of SGT-001:



              Summary of FVC Interim Functional Data of IGNITE DMD

             Absolute Change From Baseline to 1 Year and 1.5 Years

                                                                           FVC%            FVC%
                                                                           1 yr           1.5 yr
                                                                          Change          Change
                                                              1.5          from            from
                                  Baseline       1 yr         yrs        Baseline        Baseline
Patient            Patient 4
Age at Baseline    10.7 years          93.7        96.8        94.3           +3.1 %          +0.6 %
                   Patient 5
                   6.8 years           73.4       110.1        95.9          +36.7 %         +22.5 %
                   Patient 6
                   7.7 years          104.2       111.5       106.7           +7.3 %           2.5 %
Mean Change       Patients 4-6                                               +15.7 %          +8.5 %

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses